Anticonvulsant, anxiolytic, and sedative properties of the roots of Nauclea latifolia Smith in mice

Epilepsy and Behavior

Volumn 15, Issue 4, 2009, Pages 434-440

  Ngo Bum, E ^a   Taiwe, G S ^b   Moto, F C O ^b   Ngoupaye, G T ^b   Nkantchoua, G C N ^b   Pelanken, M M ^b   Rakotonirina, S V ^b   Rakotonirina, A ^b  

^a UNIVERSITY OF NGAOUNDERE   (Cameroon)

^b UNIVERSITY OF YAOUNDÉ I   (Cameroon)

Author keywords

Anxiety; Decoction; Epilepsy; Fever; Insomnia; Nauclea latifolia; Traditional medicine

Indexed keywords

CLONAZEPAM; DIAZEPAM; N METHYL DEXTRO ASPARTIC ACID; NAUCLEA LATIFOLIA EXTRACT; PENTETRAZOLE; STRYCHNINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ANTIPYRETIC ACTIVITY; ANXIETY DISORDER; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG RESPONSE; DRUG SCREENING; EPILEPSY; FEVER; INSOMNIA; MALE; MAZE TEST; MOUSE; NONHUMAN; OPEN FIELD TEST; SEDATION; SEIZURE; TRANQUILIZING ACTIVITY;

ANIMALS; ANTI-ANXIETY AGENTS; ANTICONVULSANTS; ANXIETY; CAMEROON; CONVULSANTS; DIAZEPAM; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROSHOCK; EXCITATORY AMINO ACID AGONISTS; FEVER; HYPNOTICS AND SEDATIVES; MALE; MICE; MOTOR ACTIVITY; N-METHYLASPARTATE; PENTYLENETETRAZOLE; PLANT ROOTS; RUBIACEAE; SEIZURES; SLEEP; STRESS, PSYCHOLOGICAL; STRYCHNINE;

EID: 67849116715     PISSN: 15255050     EISSN: 15255069     Source Type: Journal    
DOI: 10.1016/j.yebeh.2009.05.014     Document Type: Article

References (49)

1. Hamburger M., and Hostettman K. Bioactivity in plants: the link between phytochemistry and medicine (1991), Masson, Paris
2. Arbonnier M. Arbres, arbustes et lianes des zones sèches d'Afrique de l'Ouest. Paris: Centre de Coopération Internationale en Recherche Agronomique pour le développement/Muséum national d'histoire naturelle/Union mondiale pour la nature (CIRAD/MNHN/UICN); 2000.
3. Pousset JL. Plantes médicinales africaines. Paris: ACCT, Edition Marketing; 1989.
4. Saulnier P. Plantes médicinales et soins en Afrique (1998), Edition SEPIA, Saint-Maur
5. Gidado A., Ameh D.A., and Atawodi S.E. Effect of N. latifolia leaves aqueous extracts on blood glucose levels of normal and alloxan-induced diabetic rats. Am J Biol 4 (2005) 91-93
6. Iwu M.M. Handbook of African medicinal plants (2000), CRC Press, London/New York
7. Ouattara YJ, Simporé BJ, Sakandé IP, Guissou IZ, Kaboré L, Sawadogo. Activité hépatoprotectrice de plantes de la pharmacopée africaine vis-à-vis d'une hépatopathie expérimentale provoquée chez la souris NMRI Rev Sci Tech Sci Sante 2002;25.
8. Sourabies S., Guissou I.P., and Kabore I.Z. Mise en évidence d'une activité antibactérienne de Nauclea latifolia Sm. (Rubiaceae), vis-à-vis d'entérobactéries responsables de gastro-entérites infantiles au Burkina-Faso. Publ Med Afr 120 (1992) 18-23
9. Benoit-Vical F., Valentin A., Cournac A., Pelissier Y., and Mallie M. BastideJM. In vitro antiplasmodial activity of stem and root extracts of N. latifolia S.M. (Rubiaceae). J Ethnopharmacol 61 (1998) 173-178
10. Amos S., Abbah J., Chindo B., et al. Neuropharmacological effects of the aqueous extract of N. latifolia root bark in rats and mice. J Ethnopharmacol 97 (2005) 53-57
11. Ngo Bum E, Taiwe SG, Rakotonirina SV, Rakotonirina A. Roots of Nauclea latifolia possess anticonvulsant, anxiolytic and sedative properties in mice. In: Society for Neuroscience 37th meeting; San Diego, CA, USA; 2007. No. 660.10, p. 86.
12. Ngo Bum E, Bailabar T, Seke Etet PF, Papa Seyni, Dong C, Ayissi E. Three Cameroonian medicinal plants with sedative and anticonvulsant properties. IBRO World Congress 2007; Melbourne, Australia; 7th POS-FRI-158. p. 136.
13. Ribéreau-Gayon J., and Peynaud E. Les composés phénoliques des végétaux: traité d'œnologie (1968), Édition Dunod, Paris
14. Trease G.E., and Evans W.C. Pharmacognosy (1983), Ballière Tindall Press, London
15. Wagner H., and Bladt S. Plant drug analysis: a thin layer chromatography atlas. 2nd ed. (1996), Springer-Verlag, Berlin
16. Beretz A., Haag-Berrurier M., and Anton R. Choix de méthodes pharmacologiques pour l'étude des activités de l'aubépine. Plantes Med Phytother 4 (1978) 305-314
17. Rakotonirina S., Ngo Bum E., Rakotonirina A., and Bopelet M. Sedative properties of the decoction of the rhizome of Cyperus articulatus. Fitoterapia 72 (2001) 22-29
18. Ngo Bum E., Schmutz M., Meyer C., et al. Anticonvulsant properties of the methanolic extract of Cyperus articulatus (Cyperaceae). J Ethnopharmacol 76 (2001) 145-150
19. Ngo Bum E., Dawack D.L., Schmutz M., et al. Anticonvulsant activity of Mimosa pudica decoction. Fitoterapia 75 (2004) 310-315
20. Croucher J.M., Collins J.F., and Meldrum B.S. Anticonvulsant action of excitatory amino acids antagonists. Science 216 (1982) 899-902
21. Ngo Bum E., Ngoupaye G.T., Talla E., et al. The anticonvulsant and sedative properties of stems of Cissus quadrangularis in mice. Afr J Pharm Pharmacol 2 (2008) 42-47
22. Aguirre-Hernández E., Martínez A.L., González-Trujano M.E., Moreno J., Vibrans H., and Soto-Hernández M. Pharmacological evaluation of the anxiolytic and sedative effects of Tilia americana L. var. mexicana in mice. J Ethnopharmacol 109 (2007) 140-145
23. Bourin M., Dhonnchadha B.A., Colombel M.C., Dib M., and Hascoet M. Cyamemazine as an anxiolytic drug on the elevated plus maze and light/dark paradigm in mice. Behav Brain Res 124 (2001) 87-95
24. Lister R.G. The use of a plus-maze to measure anxiety in mouse. Psychopharmacology 92 (1987) 180-185
25. Lecci A., Borsini F., Volterra G., and Meli A. Pharmacological validation of a novel animal model of anticipatory anxiety in mice. Psychopharmacology 101 (1990) 255-261
26. Borsini F., Lecci A., Volterra G., and Meli A. A model to measure anticipatory anxiety in mice?. Psychopharmacology 98 (1989) 207-211
27. Royce J.R. On the construct validity of open field measures. Psychol Bull 84 (1977) 1098-1106
28. Prut L., and Belzung C. The open field as a paradigm to measure the effects of drugs on anxiety-like behaviors: a review. Eur J Pharmacol 463 (2003) 3-33
29. Rang H.P., Dale M.M., and Ritter J.M. Pharmacology (1999), Churchill Livingstone, London/New York
30. 3H]D-AP5 binding sites on brain membranes and anticonvulsant activity. Brain Res 382 (1986) 169-173
31. 3H]glycine binding from cortical membranes and selectively inhibit NMDA receptor-mediated neurotransmission. J Ethnopharmacol 54 (1996) 103-111
32. Mustafa A.M.S., and Ali A.M. A substance in broad beans (Vicia faba) is protective against experimentally induced convulsions in mice. Epilepsy Behav 12 (2008) 25-29
33. Fisher R.S. Animal models of the epilepsies. Brain Res Rev 14 (1989) 245-278
34. Findlay G.S., Wick M.J., Mascia M.P., et al. Transgenic expression of a mutant glycine receptor decreases alcohol sensitivity of mice. J Pharmacol Exp Ther 300 (2002) 526-534
35. Pérez-Saad H., and Buznego M.T. Behavioral and antiepileptic effects of acute administration of the extract of the plant Cestrum nocturnum Lin (lady of the night). Epilepsy Behav 12 (2008) 366-372
36. Löscher W., and Schmidt D. Which animal model should be used in the search for new antiepileptic drugs? A proposal based on experimental and clinical considerations. Epilepsy Res 2 (1988) 145-181
37. Holmes G.L. Animal model studies: application to human patients. Neurology 69 (2007) S28-S32
38. Kupferberg HJ, Schmutz M. Screening of new compounds and the role of the pharmaceutical industry. In: Engel J, Pedley TA, editors. Epilepsy: a comprehensive textbook. Philadelphia/New York: Lippincott-Raven; 1997. p. 1417-1434.
39. Olivier B., Zethof T., Pattij T., et al. Stress-induced hyperthermia and anxiety: pharmacological validation. Eur J Pharmacol 463 (2003) 117-132
40. Rodgers R.J., Cao B.J., Dalvi A., and Holmes A. Animal models of anxiety: an ethological perspective. Braz J Med Biol Res 30 (1997) 289-304
41. Deakin J.F., File S.E., Hyde J.R., and Macleod N.K. Ascending 5-HT pathways and behavioural habituation. Pharmacol Biochem Behav 10 (1979) 687-694
42. Jenck F., Moreau J.L., Martin J.R., et al. Orphanin FG acts as an anxiolytic to attenuate behavioral responses to stress. Proc Natl Acad Sci USA 94 (1997) 14854-14858
43. File S.E., and Wardill A.G. Validity of head dipping as a measure of exploration in a modified hole board. Psychopharmacologia 44 (1975) 53-59
44. Vinkers C.H., Meg J.V., Bogaert V., et al. Translational aspects of pharmacological research into anxiety disorders: the stress-induced hyperthermia (SIH) paradigm. Eur J Pharmacol 585 (2008) 407-425
45. Finn D.A. Dissecting GABAergic and serotonergic involvement in anxiety. Commentary on Belzung "The genetic basis of the pharmacological effects of anxiolytics" and Olivier et al. "The 5-HT 1A receptor knockout mouse and anxiety". Behav Pharmacol 12 (2001) 467-470
46. Tunnicliff G. Molecular basis of buspirone's anxiolytic action. Pharmacol Toxicol 69 (1991) 149-156
47. Rodgers R.J., and Davli A. Anxiety, defence and the elevated plus-maze. Neurosci Biobehav Rev 21 (1997) 801-810
48. Sundgren-Andersson A.K., Östlund P., and Bartfai T. Simultaneous measurement of brain and core temperature in the rat during fever, hyperthermia, hypothermia and sleep. Neuroimmunomodulation 5 (1998) 241-247
49. Bouwknecht J.A., Olivier B., and Paylor R.E. The stress-induced hyperthermia paradigm as a physiological animal model for anxiety: a review of pharmacological and genetic studies in the mouse. Neurosci Biobehav Rev 31 (2007) 41-59